Skip to Main Content

Try STAT+ TODAY

Exclusive

Most Read

Exclusive Megan Molteni

From fusion to retooling cancer trials, Eric Lander wants his new group to ‘go after big problems’

Exclusive Jason Mast

STAT Plus: Early findings in gene therapy death suggest CRISPR was not the cause

Exclusive Adam Feuerstein and Jason Mast

STAT Plus: FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened

Exclusive Shraddha Chakradhar and Casey Ross

The history of OxyContin, told through unsealed Purdue documents

Special Report Sheila Kaplan

To help cancer patients, lawmakers pushed access to a controversial doctor

Exclusive Casey Ross

STAT Plus: Google will let health care customers test its generative AI model, ramping up rivalry with GPT-4

Exclusive Nicholas Florko

New document reveals scope and structure of Operation Warp Speed and underscores vast military involvement

Exclusive Damian Garde

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

All Coverage

Exclusive Rachel Cohrs

The Biden administration will hang on to some Covid pandemic emergency powers

Exclusive Rachel Cohrs and John Wilkerson

STAT Plus: Senate hashing out policy details on generics, PBMs, insulin

advertisement

Exclusive Rachel Cohrs, John Wilkerson and Ed Silverman

STAT Plus: Sanders plans to haul in insulin executives to testify in Senate

Exclusive Jonathan Wosen

STAT Plus: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation

Exclusive Ed Silverman

STAT Plus: FDA report details problems at Global Pharma plant involved in eye drop recall

Exclusive Adam Feuerstein and Damian Garde

STAT Plus: Biogen’s Samantha Budd Haeberlein, an architect of Aduhelm, leaves company

Exclusive Kate Zernike

STAT Plus: How Eric Lander’s sharp elbows spurred MIT’s Nancy Hopkins to start a gender revolution

Exclusive Jason Mast

STAT Plus: Gene therapy pioneer Kathy High leaves AskBio

Exclusive John Wilkerson

STAT Plus: Senators probe telehealth companies for tracking and monetizing sensitive health data

Exclusive Sarah Owermohle

STAT Plus: HHS’ Becerra on enrolling in Medicare, annual Covid vaccines, and seniors’ mental health

Exclusive Jason Mast

STAT Plus: Calico looking for new chief scientist after celebrated biologist David Botstein quietly retires

Exclusive Matthew Herper and Casey Ross

STAT Plus: Verily leans into Onduo as it looks to enter the lucrative world of running medical research

Health Tech Matthew Herper

STAT Plus: Top Verily executives depart amid leadership shakeup and layoffs

Exclusive Jason Mast

STAT Plus: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval

Exclusive Megan Molteni

STAT Plus: Eric Lander’s next act: leading a nonprofit set on solving thorny scientific challenges

Exclusive Theresa Gaffney

STAT Plus: Backed by a longtime mental health leader, a new startup aims to build support for serious mental illness

Exclusive Katie Palmer

STAT Plus: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care

Exclusive John Wilkerson

STAT Plus: AAM’s Dan Leonard, president of generic drug lobby, ousted

Exclusive Matthew Herper, Adam Feuerstein and Jason Mast

STAT Plus: Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins

A STAT Investigation Jason Mast

STAT Plus: Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups

Exclusive Rachel Cohrs

STAT Plus: Inside Michelle McMurry-Heath’s departure from BIO: Firings, internal clashes, and a pivotal job review

Exclusive Mario Aguilar

STAT Plus: Large insurer’s decision to cover some prescription digital therapies may be a milestone for app makers

Exclusive Matthew Herper, Adam Feuerstein and Damian Garde

STAT Plus: Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate

Exclusive Rachel Cohrs

STAT Plus: Medicare tasks a senior adviser with staffing its new drug pricing division

Exclusive Mario Aguilar

STAT Plus: Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help